Biosciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.
Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.
Hum Mol Genet. 2022 Aug 23;31(16):2678-2692. doi: 10.1093/hmg/ddac060.
To evaluate potential diagnostic and therapeutic biomarkers for age-related macular degeneration (AMD), we identified 8433 UK Biobank participants with rare complement Factor I gene (CFI) variants, 579 with optical coherence tomography-derived macular thickness data. We stratified these variants by predicted gene expression and measured their association with retinal pigment epithelium-Bruch's membrane (RPE-BM) complex and retinal thicknesses at nine macular subfields, as well as AMD risk, using multivariable regression models adjusted for the common complement Factor H gene (CFH) p.Y402H and age-related maculopathy susceptibility protein 2 gene (ARMS2) p.A69S risk genotypes. CFI variants associated with low Factor I levels predicted a thinner mean RPE-BM (95% confidence interval [CI] -1.66 to -0.37 μm, P = 0.002) and retina (95% CI -5.88 to -0.13 μm, P = 0.04) and a higher AMD risk (odds ratio [OR] = 2.26, 95% CI 1.56 to 3.27, P < 0.001). CFI variants associated with normal Factor I levels did not impact mean RPE-BM/retinal thickness (P = 0.28; P = 0.99) or AMD risk (P = 0.97). CFH p.Y402H was associated with a thinner RPE-BM (95% CI -0.31 to -0.18 μm, P < 0.001 heterozygous; 95% CI -0.62 to -0.42 μm, P < 0.001 homozygous) and retina (95% CI -0.73 to -0.12 μm, P = 0.007 heterozygous; 95% CI -1.08 to -0.21 μm, P = 0.004 homozygous). ARMS2 p.A69S did not influence RPE-BM (P = 0.80 heterozygous; P = 0.12 homozygous) or retinal thickness (P = 0.75 heterozygous; P = 0.07 homozygous). p.Y402H and p.A69S exhibited a significant allele-dose response with AMD risk. Thus, CFI rare variants associated with low Factor I levels are robust predictors of reduced macular thickness and AMD. The observed association between macular thickness and CFH p.Y402H, but not ARMS2 p.A69S, highlights the importance of complement dysregulation in early pathogenesis.
为了评估与年龄相关性黄斑变性(AMD)相关的潜在诊断和治疗生物标志物,我们鉴定了 8433 名英国生物库参与者的罕见补体因子 I 基因(CFI)变体,其中 579 名参与者有光学相干断层扫描(OCT)衍生的黄斑厚度数据。我们根据预测的基因表达对这些变体进行了分层,并使用多变量回归模型测量了它们与视网膜色素上皮-脉络膜(RPE-BM)复合体以及九个黄斑亚区的视网膜厚度之间的关联,以及与 AMD 风险的关联,这些模型调整了常见的补体因子 H 基因(CFH)p.Y402H 和年龄相关性黄斑病变易感性蛋白 2 基因(ARMS2)p.A69S 风险基因型。与低因子 I 水平相关的 CFI 变体预测平均 RPE-BM(95%置信区间 [CI] -1.66 至 -0.37μm,P=0.002)和视网膜(95% CI -5.88 至 -0.13μm,P=0.04)变薄,并且 AMD 风险增加(比值比 [OR] =2.26,95% CI 1.56 至 3.27,P<0.001)。与正常因子 I 水平相关的 CFI 变体不影响平均 RPE-BM/视网膜厚度(P=0.28;P=0.99)或 AMD 风险(P=0.97)。CFH p.Y402H 与 RPE-BM 变薄相关(95% CI -0.31 至 -0.18μm,P<0.001 杂合子;95% CI -0.62 至 -0.42μm,P<0.001 纯合子)和视网膜(95% CI -0.73 至 -0.12μm,P=0.007 杂合子;95% CI -1.08 至 -0.21μm,P=0.004 纯合子)。ARMS2 p.A69S 不影响 RPE-BM(P=0.80 杂合子;P=0.12 纯合子)或视网膜厚度(P=0.75 杂合子;P=0.07 纯合子)。p.Y402H 和 p.A69S 与 AMD 风险呈显著的等位基因剂量反应关系。因此,与低因子 I 水平相关的 CFI 罕见变体是黄斑厚度和 AMD 降低的可靠预测因子。观察到的黄斑厚度与 CFH p.Y402H 之间的关联,但与 ARMS2 p.A69S 无关,突显了补体失调在早期发病机制中的重要性。